PCM
SRPT icon

Proxima Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Proxima Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-56,000
Closed -$1.18M – 51
2014
Q3 		$1.18M Buy
56,000
+6,000
+12% +$135K 0.13% 45
2014
Q2 		$1.49M Buy
+50,000
New +$1.58M 0.18% 42

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Proxima Capital Management's SRPT Position: Q4 2014 in Review

Proxima Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2014, closing a stake of 56,000 shares — an estimated $1.18M sold.

Proxima Capital Management first reported a position in SRPT in Q2 2014 and held it in 2 quarters. The position peaked at $1.49M in Q2 2014. 120 funds tracked by Wall St. Rank hold SRPT as of Q4 2014.

  • Proxima Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Proxima Capital Management sold 56,000 Sarepta Therapeutics shares in Q4 2014, an estimated $1.18M.
  • Proxima Capital Management first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 2 quarters.
  • Proxima Capital Management's Sarepta Therapeutics position peaked at $1.49M in Q2 2014.
  • 120 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2014.

Based on Proxima Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.